EP3390443A4 - Anti-myostatin-antikörper, polypeptide mit abweichenden fc-regionen und verfahren zur verwendung - Google Patents

Anti-myostatin-antikörper, polypeptide mit abweichenden fc-regionen und verfahren zur verwendung Download PDF

Info

Publication number
EP3390443A4
EP3390443A4 EP16875757.3A EP16875757A EP3390443A4 EP 3390443 A4 EP3390443 A4 EP 3390443A4 EP 16875757 A EP16875757 A EP 16875757A EP 3390443 A4 EP3390443 A4 EP 3390443A4
Authority
EP
European Patent Office
Prior art keywords
regions
methods
polypeptides containing
myostatin antibodies
containing variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16875757.3A
Other languages
English (en)
French (fr)
Other versions
EP3390443A1 (de
Inventor
Taichi Kuramochi
Tomoyuki Igawa
Hitoshi KATADA
Yuji Hori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP3390443A1 publication Critical patent/EP3390443A1/de
Publication of EP3390443A4 publication Critical patent/EP3390443A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
EP16875757.3A 2015-12-18 2016-12-16 Anti-myostatin-antikörper, polypeptide mit abweichenden fc-regionen und verfahren zur verwendung Pending EP3390443A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015247070 2015-12-18
PCT/JP2016/087487 WO2017104783A1 (en) 2015-12-18 2016-12-16 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Publications (2)

Publication Number Publication Date
EP3390443A1 EP3390443A1 (de) 2018-10-24
EP3390443A4 true EP3390443A4 (de) 2019-11-13

Family

ID=59011957

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16875757.3A Pending EP3390443A4 (de) 2015-12-18 2016-12-16 Anti-myostatin-antikörper, polypeptide mit abweichenden fc-regionen und verfahren zur verwendung

Country Status (16)

Country Link
EP (1) EP3390443A4 (de)
JP (4) JP6142069B1 (de)
KR (3) KR102501335B1 (de)
CN (2) CN108473562B (de)
AR (1) AR107078A1 (de)
AU (1) AU2016372934B2 (de)
BR (1) BR112018011073A2 (de)
CA (1) CA3002422C (de)
EA (1) EA201891420A1 (de)
HK (1) HK1254755A1 (de)
MX (1) MX2018007145A (de)
MY (1) MY189425A (de)
PH (1) PH12018501280A1 (de)
SG (2) SG11201610812WA (de)
TW (3) TW202231662A (de)
WO (1) WO2017104783A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
EP3689912A1 (de) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstitution in cdr
EP4238993A3 (de) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Antigenbindendes molekül zur wiederholten bindung an zwei oder mehr antigenmoleküle
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JPWO2013180200A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 標的組織特異的抗原結合分子
TWI697501B (zh) 2012-08-24 2020-07-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
JP7060317B2 (ja) 2013-12-04 2022-04-26 中外製薬株式会社 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3394098A4 (de) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin-antikörper und verfahren zur verwendung
MY193497A (en) * 2016-06-17 2022-10-17 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies and methods of use
EP3494991A4 (de) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Zusammensetzung zur vorbeugung oder behandlung von erkrankungen im zusammenhang mit il-8
SG11201907288RA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Cysteine mutated antibodies for conjugation
KR102259473B1 (ko) 2018-08-10 2021-06-02 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
MX2021012251A (es) * 2019-04-10 2021-11-12 Chugai Pharmaceutical Co Ltd Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc).
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
WO2023057404A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Novel combined administration
WO2023187022A1 (en) 2022-04-01 2023-10-05 F. Hoffmann-La Roche Ag New treatment for facioscapulohumeral muscular dystrophy (fshd)
US11780910B1 (en) 2022-05-02 2023-10-10 Novo Nordisk A/S Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
WO2024081932A1 (en) 2022-10-14 2024-04-18 Genentech, Inc. Methods for treating spinal muscular atrophy
CN116990528B (zh) * 2023-09-27 2024-02-06 成都华西海圻医药科技有限公司 一种基于Gyrolab平台快速测定抗CD40单抗的分析方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027248A2 (en) * 2001-09-26 2003-04-03 Wyeth Antibody inhibitors of gdf-8 and uses thereof
EP2889377A1 (de) * 2012-08-24 2015-07-01 Chugai Seiyaku Kabushiki Kaisha Fc-riib-spezifische fc-regionsvariante
EP3240804A1 (de) * 2014-12-19 2017-11-08 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin-antikörper, polypeptide mit abweichenden fc-regionen und verfahren zur verwendung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
EP1797127B1 (de) * 2004-09-24 2017-06-14 Amgen Inc. Modifizierte fc-moleküle
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
PT2066695E (pt) * 2006-09-05 2013-05-23 Lilly Co Eli Anticorpos anti-miostatina
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP4238993A3 (de) * 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Antigenbindendes molekül zur wiederholten bindung an zwei oder mehr antigenmoleküle
AR074777A1 (es) * 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
CN102844332B (zh) * 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
AR081556A1 (es) * 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
LT2825036T (lt) * 2012-03-16 2018-07-10 Regeneron Pharmaceuticals, Inc. Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti graužikai, išvesti ju gamybai
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
NZ704771A (en) * 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
EP3816625A1 (de) * 2013-05-06 2021-05-05 Scholar Rock, Inc. Zusammensetzungen und verfahren zur modulation von wachstumsfaktoren
RU2016108652A (ru) * 2013-08-14 2017-09-14 Новартис Аг Способы лечения спорадического миозита с тельцами включений
JP6706617B2 (ja) * 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
WO2016073906A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027248A2 (en) * 2001-09-26 2003-04-03 Wyeth Antibody inhibitors of gdf-8 and uses thereof
EP2889377A1 (de) * 2012-08-24 2015-07-01 Chugai Seiyaku Kabushiki Kaisha Fc-riib-spezifische fc-regionsvariante
EP3240804A1 (de) * 2014-12-19 2017-11-08 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin-antikörper, polypeptide mit abweichenden fc-regionen und verfahren zur verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOHN O RICHARDS ET AL: "Optimization of antibody binding to FcãRIIa enhances macrophage phagocytosis of tumor cells", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 7, no. 8, 1 August 2008 (2008-08-01), pages 2517 - 2527, XP002631327, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-08-0201 *

Also Published As

Publication number Publication date
KR20230027321A (ko) 2023-02-27
TWI605057B (zh) 2017-11-11
PH12018501280A1 (en) 2019-01-28
CN115028721A (zh) 2022-09-09
BR112018011073A2 (pt) 2018-11-21
JP2017112997A (ja) 2017-06-29
MX2018007145A (es) 2018-08-15
AU2016372934B2 (en) 2023-10-05
TWI749057B (zh) 2021-12-11
CA3002422C (en) 2024-04-16
WO2017104783A1 (en) 2017-06-22
EA201891420A1 (ru) 2019-02-28
TW202231662A (zh) 2022-08-16
KR101820637B1 (ko) 2018-01-19
CN108473562A (zh) 2018-08-31
TW201726718A (zh) 2017-08-01
CN108473562B (zh) 2022-06-17
MY189425A (en) 2022-02-10
JP2017148069A (ja) 2017-08-31
SG11201610812WA (en) 2017-07-28
CA3002422A1 (en) 2017-06-22
KR20170085028A (ko) 2017-07-21
EP3390443A1 (de) 2018-10-24
KR102501335B1 (ko) 2023-02-17
AR107078A1 (es) 2018-03-21
RU2018125431A3 (de) 2020-07-06
JP7053164B2 (ja) 2022-04-12
SG10201707267RA (en) 2017-10-30
TW201808992A (zh) 2018-03-16
RU2018125431A (ru) 2020-01-20
JP6142069B1 (ja) 2017-06-07
HK1254755A1 (zh) 2019-07-26
AU2016372934A1 (en) 2018-05-10
JP2022097485A (ja) 2022-06-30
JP2024023427A (ja) 2024-02-21
KR20180085711A (ko) 2018-07-27

Similar Documents

Publication Publication Date Title
IL278014A (en) Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
HK1254755A1 (zh) 抗-肌肉生長抑制因子抗體、包含變體fc區的多肽及使用方法
IL264590A (en) fc region-containing polypeptides and uses thereof
EP3472200A4 (de) Anti-myostatin-antikörper und verfahren zur verwendung
EP3377102A4 (de) Anti-pd-1-antikörper und deren therapeutische verwendungen
EP3299383A4 (de) Spezifische änderung von antikörpern mit igg-bindendem peptid
EP3137505A4 (de) Kombination von lenalidomid und polypeptidkonstrukt und verwendungen davon
EP3241850A4 (de) Glp und hybrides immunglobulin-fc-kondensiertes polypeptid und verwendung davon
EP3237450A4 (de) Anti-mertk-antikörper und verwendungen davon
EP3512879A4 (de) Anti-dengue-virus-antikörper, polypeptide mit abweichenden fc-regionen und verfahren zur verwendung
EP3122783A4 (de) Neuartige rekombinante bifunktionelle fusionsproteine, herstellung und verwendung davon
EP3394098A4 (de) Anti-myostatin-antikörper und verfahren zur verwendung
EP3104870A4 (de) Tau-peptide, anti-tau-antikörper und verfahren zur verwendung davon
EP3236772A4 (de) Verfahren zur aufreinigung von rekombinanten proteinen
EP3328429A4 (de) Peptide und antikörper zur beseitigung von biofilmen
EP3233916A4 (de) Humanisierte anti-acth-antikörper und verwendungen davon
EP3341021A4 (de) Anti-alk-antikörper und verfahren zur verwendung davon
EP3280440A4 (de) Humanisierte anti-c1s-antikörper und verfahren zur verwendung davon
EP3400239A4 (de) Tetravalente anti-psgl-1-antikörper und verwendungen davon
EP3199555A4 (de) Formulierung aus rekombinantem fusionsprotein
EP3199179A4 (de) Formulierung aus rekombinantem fusionsprotein
EP3285805A4 (de) Therapeutische antikörper und verwendungen davon
EP3315515A4 (de) Fusionsproteinhaltiges bdnf
EP3270918A4 (de) Anti-met-antikörper und verfahren zur verwendung davon
EP3096784A4 (de) Peptide, vorrichtungen und verfahren zum nachweis von anaplasma-antikörpern

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101AFI20190723BHEP

Ipc: C12N 15/09 20060101ALI20190723BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20191014

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101AFI20191008BHEP

Ipc: C12N 15/09 20060101ALI20191008BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200921

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS